Glaxo Wellcome Inc.

Martin John Page

George Stuart Cockerill

Alan T Hudson

Stephen Barry Guntrip

Kathryn Jane Smith

Karl Witold Franzmann

Paul Barraclough

Sadie Vile

Mark Roger Crompton

Barry Austin Gusterson

Karen Tracey Barker

Taherah Kamalati

Stephen Carl McKeown

Paul Spence

Philip John Mitchell

Substituted heteroaromatic compounds of formula (A) wherein X is N or CH; in which (a) represents a fused 5, 6 or 7-membered heterocyclic ring and R,is a group ZR,wherein Z is joined to R,through a (CH,)p group in which p is 0, 1, or 2 and Z represents a group V(CH,), V(CF,), (CH,)V, (CF,)V, V(CRR&prime;), V(CHR) or V where R and R&prime; are each C,alkyl and in which V is a hydrocarbyl group containing 0, 1 or 2 carbon atoms, carbonyl, dicarbonyl, CH(OH), CH(CN), sulphonamide, amide, O, S(O),or NR,where R,is hydrogen or R,is C,alkyl; and R,is an optionally substituted C,cycloalkyl or an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety; or R,is a group ZR,in which Z is NR,, and NR,and R,together form an optionally substituted 5, 6, 7, 8, 9 or 10-membered carbocyclic or heterocyclic moiety, are protein tyrosine kinase inhibitors. The compounds are described, as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of psoriasis, fibrosis, atherosclerosis, restenosis, auto-immune disease, allergy, asthma, transplantation rejection, inflammation, thrombosis, nervous system diseases, and cancer.

Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors

BRK protein tyrosine kinase and encoding nucleic acid

Growing community of inventors

Abingdon, United Kingdom

Martin John Page